© 2026, NOVARHYTHM BIOSCIENCES.
SAR-297871 is an orally available, small-molecule inhibitor of the TASK-1 (K2P3.1) potassium channel, originally developed by Sanofi for the treatment of atrial fibrillation (AF). Extensive preclinical research and human cardiac tissue data support its potent, atrial-focused activity and differentiated safety profile.
NovaRhythm has in-licensed SAR-297871 from Sanofi and now holds exclusive global rights to advance the program through IND-enabling studies, clinical development and commercialization.
In atrial fibrillation (AF), abnormal electrical activity in the atria disrupts the heart’s normal rhythm and rate, leading to rapid, irregular beating. A key contributor to this process is the TASK-1 potassium channel, which is upregulated in atrial tissue of AF patients and contributes to shortened action potential duration, promoting re-entry and ectopic firing.
NovaRhythm’s data identifies TASK-1 channel as a breakthrough target for treating atrial fibrillation (AF). Our lead compound, SAR-297871, is a selective TASK-1 inhibitor designed to eliminate arrhythmic behaviors and triggered contractions, restore normal atrial rhythm and rate, and validate a powerful new pathway for the future of AF treatment.
NovaRhythm data from atrial cells of AF donors demonstrates how SAR-297871 counteracts action potential (AP) shortening – a key driver of atrial electrical remodeling and AF. By prolonging the AP duration across different repolarization stages, SAR-297871 helps re-balance electrical activity and prevent rhythm disorders.
SAR-297871 demonstrates high safety profile through its atrial-selective profile. Studies on ventricular trabeculae and cardiomyocytes from normal donor hearts show no impact on ventricular function, confirming a significantly lower risk of cardiotoxicity and proarrhythmia.